Obicetrapib vs Obicetrapib/ezetimibe (Evlarco)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: CETP · full Atherosclerotic Cardiovascular Disease pipeline
Obicetrapib
Marketed by A. Menarini under a licence from NewAmsterdam Pharma
NCT05142722 · Phase 3 · completed
Participants were randomized 2:1 to obicetrapib or placebo and the trial was quadruple-blinded, with 2,530 participants enrolled. The primary LDL-cholesterol endpoint was met, with a statistically significant treatment difference, but LDL cholesterol is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure, supporting a moderate grade.
Next expected readout: November 2026 · NCT06496243 (registry estimate)
Reported efficacy
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571) (met)
Result source: NCT05142722
Obicetrapib/ezetimibe (Evlarco)
Marketed by A. Menarini under a licence from NewAmsterdam Pharma
NCT06005597 · Phase 3 · completed
The study was randomized, quadruple-blind, and placebo- and active-controlled, with 407 participants distributed across four treatment groups. All four prespecified LDL-C comparisons significantly favored the obicetrapib-containing treatment, but LDL-C is a laboratory surrogate rather than a hard clinical endpoint, so the evidence is rated moderate.
Reported efficacy
Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-C (84 Days); Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-C (84 Days): Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) (met)
Result source: NCT06005597
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Obicetrapib | Obicetrapib/ezetimibe (Evlarco) |
|---|---|---|
| LDL-C, % change | -29.9% vs 2.7%−32.6 vs placeboNCT0514272268 other results
| —Not reported |
| Non-HDL-C, % change | -22.4% vs 0.6%−23 vs placeboNCT0514272223 other results
| —Not reported |
| ApoB, % change | -15.6% vs -1.8%−13.8 vs placeboNCT0514272238 other results
| —Not reported |
| Lp(a), % change | -0.5% vs 13.7%−14.1 vs placeboNCT051427223 other results
| —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT05202509 | —Not reported |
LDL-C, % change
- Obicetrapib
- -29.9% vs 2.7%−32.6 vs placeboNCT05142722
68 other results
- -36.0% vs 0.3% NCT05425745
- -45.6% vs 3.0% NCT06005597
- -28.8% vs 3.0% NCT06005597
- -45.6% vs -17.6% NCT06005597
- -25.3% vs -1.3% NCT05142722
- -29.1% vs 4.7% NCT05142722
- -31.1% vs 10.3% NCT05425745
- -31.8% vs 6.0% NCT05425745
- -36.8% vs -0.8% NCT05421078
- -45.8% vs -0.9% NCT05421078
- -36.6% vs -0.5% NCT05421078
- -36.3% vs 0.4% NCT05421078
- -43.7% vs 0.7% NCT05421078
- -36.1% vs 0.7% NCT05421078
- -43.4% vs -5.5% NCT04753606
- -45.6% vs 0% NCT04753606
- -44.2% vs -5% NCT04753606
- -46.1% vs -7.1% NCT04753606
- -50.8% vs -6.5% NCT04753606
- -46.8% vs -6.7% NCT04753606
- -33.8% vs -0.8% NCT05421078
- -31.9% vs -0.9% NCT05421078
- -33.8% vs -0.5% NCT05421078
- -30.5% vs 0.4% NCT05421078
- -30.4% vs 0.7% NCT05421078
- -30.5% vs 0.7% NCT05421078
- -38.0% vs -5.5% NCT04753606
- -42.9% vs 0% NCT04753606
- -38.0% vs -5% NCT04753606
- -36.0% vs -7.1% NCT04753606
- -41.5% vs -6.5% NCT04753606
- -35.6% vs -6.7% NCT04753606
- -25.9% vs -0.8% NCT05421078
- -24.8% vs -0.9% NCT05421078
- -26.3% vs -0.5% NCT05421078
- -26.1% vs 0.4% NCT05421078
- -26.0% vs 0.7% NCT05421078
- -26.5% vs 0.7% NCT05421078
- -59.1% vs -0.8% NCT05266586
- -63.4% vs -6.3% NCT05266586
- -59.2% vs -0.8% NCT05266586
- -59.5% vs -1.5% NCT05266586
- -62.8% vs -4.0% NCT05266586
- -59.7% vs -1.5% NCT05266586
- -45.6% vs -0.2% NCT04770389
- -52.0% vs -1.4% NCT04770389
- -43.5% vs 1.4% NCT04770389
- -44.4% vs -1.5% NCT04770389
- -51.4% vs -2% NCT04770389
- -44.1% vs -0.8% NCT04770389
- -39.4% vs -0.8% NCT05266586
- -43.5% vs -6.3% NCT05266586
- -39.2% vs -0.8% NCT05266586
- -39.0% vs -1.5% NCT05266586
- -43.5% vs -4.0% NCT05266586
- -38.8% vs -1.5% NCT05266586
- -31.9% vs -0.2% NCT04770389
- -34.4% vs -1.4% NCT04770389
- -32.0% vs 1.4% NCT04770389
- -27.9% vs -1.5% NCT04770389
- -30.1% vs -2% NCT04770389
- -29.0% vs -0.8% NCT04770389
- -45.6% vs -12.7% NCT04770389
- -52.0% vs -14.8% NCT04770389
- -43.5% vs -13.4% NCT04770389
- -31.9% vs -12.7% NCT04770389
- -34.4% vs -14.8% NCT04770389
- -32.0% vs -13.4% NCT04770389
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
Non-HDL-C, % change
- Obicetrapib
- -22.4% vs 0.6%−23 vs placeboNCT05142722
23 other results
- -24.6% vs 3.7% NCT05142722
- -26.6% vs 2.8% NCT05142722
- -25.8% vs 11.6% NCT05425745
- -27.1% vs 5.9% NCT05425745
- -31.6% vs 2.8% NCT05425745
- -42.4% vs 2.7% NCT06005597
- -27.2% vs 2.7% NCT06005597
- -42.4% vs -17.0% NCT06005597
- -30.3% vs -1.8% NCT05421078
- -37.0% vs -0.4% NCT05421078
- -30.3% vs -1.7% NCT05421078
- -39.3% vs -4.2% NCT04753606
- -44.4% vs -3.5% NCT04753606
- -39.9% vs -3.8% NCT04753606
- -30.4% vs -1.8% NCT05421078
- -29.8% vs -0.4% NCT05421078
- -30.1% vs -1.7% NCT05421078
- -34.3% vs -4.2% NCT04753606
- -38.9% vs -3.5% NCT04753606
- -34.4% vs -3.8% NCT04753606
- -25.4% vs -1.8% NCT05421078
- -23.7% vs -0.4% NCT05421078
- -25.7% vs -1.7% NCT05421078
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
ApoB, % change
- Obicetrapib
- -15.6% vs -1.8%−13.8 vs placeboNCT05142722
38 other results
- -16.1% vs 2.2% NCT05142722
- -17.8% vs 1.1% NCT05142722
- -17.6% vs 8.2% NCT05425745
- -18.3% vs 6.0% NCT05425745
- -21.4% vs 2.9% NCT05425745
- -26.9% vs 2.3% NCT06005597
- -17.5% vs 2.3% NCT06005597
- -26.9% vs -12.7% NCT06005597
- -21.7% vs 0.5% NCT05266586
- -24.2% vs -2.0% NCT05266586
- -21.6% vs 0.7% NCT05266586
- -26.7% vs -1.2% NCT05421078
- -29.7% vs -0.4% NCT05421078
- -26.3% vs -1.4% NCT05421078
- -27.2% vs -4.7% NCT04753606
- -29.8% vs -2.6% NCT04753606
- -28.1% vs -4.1% NCT04753606
- -24.5% vs -1.2% NCT05421078
- -21.4% vs -0.4% NCT05421078
- -23.9% vs -1.4% NCT05421078
- -22.6% vs -4.7% NCT04753606
- -24.4% vs -2.6% NCT04753606
- -22.4% vs -4.1% NCT04753606
- -19.8% vs -1.2% NCT05421078
- -22.5% vs -0.4% NCT05421078
- -20.4% vs -1.4% NCT05421078
- -34.7% vs 0.5% NCT05266586
- -34.4% vs -2.0% NCT05266586
- -35.0% vs 0.7% NCT05266586
- -31.6% vs -1.2% NCT04770389
- -34.8% vs -0.9% NCT04770389
- -29.7% vs -0.1% NCT04770389
- -22.1% vs -1.2% NCT04770389
- -23.5% vs -0.9% NCT04770389
- -22.5% vs -0.1% NCT04770389
- -31.6% vs -8.8% NCT04770389
- -34.8% vs -8.9% NCT04770389
- -29.7% vs -8.9% NCT04770389
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
Lp(a), % change
- Obicetrapib
- -0.5% vs 13.7%−14.1 vs placeboNCT05142722
3 other results
- -32.3% vs -0.9% NCT05142722
- -29.9% vs 24.4% NCT05425745
- -35.4% vs 10.5% NCT05425745
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
3-point MACE (% with event)
- Obicetrapib
- —Trial running · NCT05202509
- Obicetrapib/ezetimibe (Evlarco)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Obicetrapib: 4 of 4 rows · Obicetrapib/ezetimibe (Evlarco): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Obicetrapib |
|---|---|
| Dropout rate | 5.1%10mga NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 12 more results4.2%10 mg NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2%Fixed Dose Combination NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 2.9%Monotherapy Obicetrapib NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%10 mg NCT05421078 · Phase 2 · registry result, not featured evidence 0%5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 0%2.5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 7.7%10 mg NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy 5%Combination Therapy NCT05266586 · Phase 2 · registry result, not featured evidence · combination 0%10 mg NCT04753606 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04753606 · Phase 2 · registry result, not featured evidence 18.5%Combination Therapy NCT04770389 · Phase 2 · registry result, not featured evidence · combination 7.1%Obicetrapib Monotherapy NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | 0.1%10mga NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 12 more results0.4%10 mg NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Fixed Dose Combination NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —Monotherapy Obicetrapib NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —10 mg NCT05421078 · Phase 2 · registry result, not featured evidence —5 mg NCT05421078 · Phase 2 · registry result, not featured evidence —2.5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 5.1%10 mg NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy 2.5%Combination Therapy NCT05266586 · Phase 2 · registry result, not featured evidence · combination 0%10 mg NCT04753606 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04753606 · Phase 2 · registry result, not featured evidence 7.4%Combination Therapy NCT04770389 · Phase 2 · registry result, not featured evidence · combination 0%Obicetrapib Monotherapy NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy |
| Serious AEs | 12.5%10mga NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 12 more results5.6%10 mg NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.9%Fixed Dose Combination NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 5.9%Monotherapy Obicetrapib NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%10 mg NCT05421078 · Phase 2 · registry result, not featured evidence 4%5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 0%2.5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 2.6%10 mg NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy 0%Combination Therapy NCT05266586 · Phase 2 · registry result, not featured evidence · combination 0%10 mg NCT04753606 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04753606 · Phase 2 · registry result, not featured evidence 0%Combination Therapy NCT04770389 · Phase 2 · registry result, not featured evidence · combination 0%Obicetrapib Monotherapy NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | 10mga hypertension 4.9% (placebo 3.9%) covid-19 4.8% (placebo 5.7%) upper respiratory tract infection 2.9% (placebo 3.9%) NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 12 more results10 mg influenza 9% (placebo 5.9%) covid-19 6.4% (placebo 6.8%) nasopharyngitis 6.4% (placebo 4.2%) NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 diarrhoea 4.9% (placebo 0%) covid-19 3.9% (placebo 1%) fatigue 3.9% (placebo 1%) NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 hypertension 8.8% (placebo 2.9%) arthralgia 6.9% (placebo 2.9%) headache 5.9% (placebo 2%) NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 10 mg back pain 7.7% (placebo 11.5%) nasopharyngitis 7.7% (placebo 11.5%) rhinitis allergic 7.7% (placebo 0%) NCT05421078 · Phase 2 · registry result, not featured evidence 5 mg blood glucose increased 4% (placebo 0%) blood pressure increased 4% (placebo 0%) chest pain 4% (placebo 0%) NCT05421078 · Phase 2 · registry result, not featured evidence 2.5 mg diabetes mellitus 8% (placebo 0%) hypoglycaemia 8% (placebo 0%) abdominal distension 4% (placebo 0%) NCT05421078 · Phase 2 · registry result, not featured evidence 10 mg abdominal pain 2.6% (placebo 0%) abdominal pain upper 2.6% (placebo 0%) acute myocardial infarction 2.6% (placebo 0%) NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy nausea 5% (placebo 5%) arthralgia 2.5% (placebo 2.5%) bronchitis 2.5% (placebo 0%) NCT05266586 · Phase 2 · registry result, not featured evidence · combination 10 mg arthralgia 2.5% (placebo 2.5%) arthropod sting 2.5% (placebo 0%) cardiomegaly 2.5% (placebo 0%) NCT04753606 · Phase 2 · registry result, not featured evidence 5 mg fatigue 5% (placebo 5%) hypertension 5% (placebo 0%) type 2 diabetes mellitus 5% (placebo 0%) NCT04753606 · Phase 2 · registry result, not featured evidence diarrhoea 7.4% (placebo 0%) abdominal pain 3.7% (placebo 0%) back pain 3.7% (placebo 0%) NCT04770389 · Phase 2 · registry result, not featured evidence · combination covid-19 3.6% (placebo 0%) flatulence 3.6% (placebo 0%) onychomycosis 3.6% (placebo 0%) NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 9 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Obicetrapib
show 68 more results
show 38 more results
show 23 more results
show 20 more results
show 3 more results
show 5 more results
show 5 more results
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Obicetrapib's landscape · Obicetrapib/ezetimibe (Evlarco)'s landscape